Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

Radient Restructured By A Planned Reverse Merger

This is All The DD and Rebuttals with ALL of the facts you will ever need to know in ONE Quick Link and Page; Why Radient Pharmaceuticals Public Shell will be utilized for The Proposed LOI of 2010 to reverse Merge with Provista Diagnostics.

Radient Pharmaceuticals Corporation (AMEX: RPC) announced today that it has entered into a letter of intent (LOI) to acquire Provista Diagnostics Inc. (PDI), a Nevada corporation offering laboratory testing services that meet the Clinical Laboratory Improvement Act (CLIA) guidelines. Radient Pharmaceuticals intends to acquire PDI, in a stock-for-stock transaction, when respective due diligence for both companies is successfully completed.

http://www.streetinsider.com/Mergers+and+Acquisitions/Radient+Pharma+%28RPC%29+Enters+LoI+to+Acquire+Provista+Diagnostics/5800576.html

http://www.proactiveinvestors.com/companies/news/11423/radient-pharmaceuticals-speculation-intensifies-over-commercial-potential-of-onko-sure-cancer-diagnostic-test-11423.html



For reverse mergers involving a public shell, the private company can control as much as 80-90% of the outstanding shares of common stock. The remaining 10-20% is held by the previous shareholders of the public shell and by promoters of the merger.

http://www.publicshellco.com/content6.html

Reverse Mergers
06/09/2011
Introduction

Many private companies, including some whose operations are located in foreign countries, seek to access the U.S. capital markets by merging with existing public companies. These transactions are commonly referred to as “reverse mergers” or “reverse takeovers (RTOs).”

http://m.investor.gov/news-alerts/investor-bulletins/reverse-mergers



5/18/2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113767528


Runn Stated:

runncoach Sunday, 05/17/15 03:59:21 PM
Re: guardiangel post# 29375
Post # of 29376

So Dominion Resources publicly trades under what symbol currently?

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113750577


Run..It is Dominion Minerals not Dominion Resources which is a subsidiary of Dominion Power of Virginia..As we explained in our previous post, Dominion is not trading. If they were trading they would have to file a Form 15c2-11. here is a company similar to Radient Pharmaceuticals situation..

http://usfuelcorporation.com/wp-content/uploads/2014/02/USFF_PR_12j-Order-00014099-6.pdf

Radient Pharmaceutical and Dominion are Shell corporations. Living stated that Dominion was a private company..This is not true. Dominion filed a 10-12G to register their stock after their voluntary revocation..Here is a link to help you better understand..Now that they registered their stock they are a public corporation not trading. They are still using the same ticker..It appears they are going to either reverse merge again or wait to find a market maker..

The filing of the 10-12G will be the first step for Radient.
Then they will merge with be able to merge according to the 2010LOI with Provista Diagnostics. Once the merger is approved by shareholders of both corporations and shares exchanged, then the new Radient corporation can file their 15c2-11..This is how it works..Glad to be of assistance to you..Wolfie

Here is an example from USFF they too filed a voluntary revocation of their stock..

http://usfuelcorporation.com/wp-content/uploads/2014/02/USFF_PR_12j-Order-00014099-6.pdf

Here is the definition of a 10-12G

http://www.investopedia.com/terms/s/sec-form-10-12g.asp


RUNN Dominion registered the same stock in their 10-12G

10-K filing 2009 Page 2....

Common stock, $0.0001 par value; 700,000,000 shares authorized

73,103,362 and 42,605,696 issued an
d outstanding as of December 31, 2008 and 2007, respectively

http://www.sec.gov/Archives/edgar/data/1402747/000114420409027836/v149980_10k.htm

10-12G Filing....2014


The authorized and outstanding capital of the Company consists of 700,000,000 shares of $.0001 par value common stock and 5,000,000 shares of $.0001 par value preferred stock. As of October 13, 2014, there were 96,445,678 outstanding shares of common stock and 200 shares of Series A, preferred stock, outstanding.

http://www.sec.gov/Archives/edgar/data/1402747/000121390014007607/f1012g2014_dominion.htm






***************************************************************


This is why Provista Diagnostics wants to reverse merge with Radient Pharmaceuticals according to the lOI of 2010....

5/17/2015


Now that we have proved the fallacy that a void and revoked Delaware Corporation cannot trade again with the Dominion Minerals Corp, that is similar to Radient Pharmaceuticals, we can also conclude that being VOID in Delaware is simply irrelevant.. Here is an example of a Delaware Corporation that revoked their shares on a voluntary basis and is Trading under a new symbol...The Company was reverse merged when the Stock was re-instated. The Dominion Minerals Corp is getting ready for a Reverse Merger.It is also a Public Shell similar to Radient once William and David decide to reverse merge and go Public...In answer to your question...It depends on which ticker David and William have decided on you understand...


runncoach Sunday, 05/17/15 12:18:14 PM
Re: guardiangel post# 29371
Post # of 29374

Can we get a ticker symbol that trades under. I would like to see how that's played out then. TIA

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113747661

and the Ferris wheels keep on spinning...Still stand in correct you understand.......ahoololoooololooooooo

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113747574

10-12G Documents [Cover]Registration of securities [Section 12(g)]
Acc-no: 0001144204-11-053134 (34 Act) Size: 1 MB 2011-09-14 000-30291
111092278
REVOKED Documents Commission order revoking Exchange Act registration [Section 12(j)]
Acc-no: 9999999997-12-008017 (34 Act) Size: 56 KB 2011-02-09 000-30291
12763757

Temporarily Revocation Letter from SEC for Hemiwedge before they were reversed merged into HII Technologies...

http://www.sec.gov/Archives/edgar/data/1085254/999999999712008017/filename1.pdf

http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001085254&type=&dateb=&owner=exclude&start=40&count=40

Radient Pharmaceuticals Corporation letter from SEC for Voluntarily revoking RXPC Shares..Same as Hemiwedge before they reverse merged with HII Technologies...

http://www.sec.gov/Archives/edgar/data/838879/999999999714011663/filename1.pdf

http://www.sec.gov/cgi-bin/browse-edgar?company=Radient+Pharmaceuticals&owner=exclude&action=getcompany


10-12G Documents Registration of securities [Section 12(g)]
Acc-no: 0001213900-14-007607 (34 Act) Size: 1 MB 2014-10-31 000-52696
141184196

REVOKED Documents Commission order revoking Exchange Act registration [Section 12(j)]
Acc-no: 9999999997-12-014580 (34 Act) Size: 24 KB 2012-11-16 000-52696
121210317

http://www.sec.gov/cgi-bin/browse-edgar?company=Dominion+Minerals+Corp&match=&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany&Find=Search


Here is a link to the 10-12G that Dominion Minerals filed to reinstate their Revocated Stock..and a description to the Stocholder equity...When Dominion is ready to Trade their stock, it is ready to go public at anytime...


5.Shareholders’ equity

The Company is authorized to issue 705,000,000 shares: 700,000,000 shares of $0.0001 par value common stock and 5,000,000 shares of $0.0001 par value preferred stock. As of December 31, 2013, the Company has 86,445,678 shares of common stock outstanding and 200 shares of Series A preferred stock outstanding.

http://www.sec.gov/Archives/edgar/data/1402747/000121390014007607/f1012g2014_dominion.htm


****************************************************************
5/17/2015

Radient Restructured By A Planned Reverse Merger

This statement of opinion ("no corporation has ever returned from REVOKED and VOID") posted below is not true. A Corporation incorporated in Delaware, Dominion Minerals Corporation voluntarily revoked their shares with the SEC for not filing two years of annual reports and were also a VOID Delaware Corporation. Radient Pharmaceuticals was also Voluntarily revoked by Mac for not filing their annual reports for two years and was also a VOID Delaware Corporation. We will present these facts with links to the SEC letter for Radient and Dominion Minerals to show and prove the similar situations....

Dominion Minerals filed a 10-12G on 10/31/14 to have their stock reinstated and registered with the SEC..The company stocks were revoked on 11/16/12. Almost two years before they filed their updated annual reports to reinstate their Stock with the SEC and re-instate their Delaware corporation.

livinginsv Saturday, 05/16/15 02:08:39 PM
Re: runncoach post# 29366
Post # of 29370

"no corporation has ever returned from REVOKED and VOID"

i'm sure many private companies in DE have been reinstated from void . . . and many publicly traded stocks have returned from being revoked . . .

the combination of being both REVOKED and VOID has always been THE END for every publicly traded ticker . . .

RXPC IS REVOKED AND VOID . . . and this is not a history making shell . . . maybe in 2021, that's all the hope there is here .

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113735112 . .

****************************************************************

Radient Pharmaceuticals Corporation

REVOKED Documents Commission order revoking Exchange Act registration [Section 12(j)]
Acc-no: 9999999997-14-011663 (34 Act) Size: 29 KB 2014-07-03 000-27689
14958860

http://www.sec.gov/cgi-bin/browse-edgar?company=Radient+Pharmaceuticals&owner=exclude&action=getcompany

UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION
SECURITIES EXCHANGE ACT OF 1934
Release No.
72529 / July 3, 2014
ADMINISTRATIVE PROCEEDING
File No.
3
-
15962
In
the Matter of
Radient Pharmaceuticals Corporation
,
Respondent.
ORDER INSTITUTING PROCEEDINGS,
MAKING FINDINGS, AND REVOKING
REGISTRATION OF SECURITIES
PURSUANT TO SECTION 12(j) OF THE
SECURITIES EXCHANGE ACT OF 1934
I.
The Securities and Exchange Commission (“Commission”) deems it necessary
and appropriate for the protection of investors that proceedings be, and hereby are,
instituted pursuant to Section 12(j) of the Securities Exchange Act of 1934 (“Exchange
Act”), agai
nst
Radient Pharmaceuticals Corporation
(“
RXPC
” or “Respondent”).
II.
In anticipation of the institution of these proceedings,
RXPC
has submitted an
Offer of Settlement (the “Offer”) which the Commission has determined to accept.

1.
RXPC
(CIK No.
838879
) is
a void
Delaware
corporation
located in
Tustin, California
with a class of securities registered with the Commission
under
Exchange Act Section 12.
As of
April 9, 2014
, the
common stock
of
RXPC
(symbol
RXPC
)
was
quoted on OTC Link
(formerly “Pink Sheets”) operated by
2
OTC Markets Group Inc.
, had
ten
market makers, and was eligible for the
piggyback exception of Exchange Act Rule 15c2
-
11(f)(3).
2.
RXPC
has failed to comply with Exchange Act Section 13(a) and
Rules 13a
-
1 and 13a
-
13 thereunder because it has not filed any periodic reports
with the C
ommission since the period ended
December 31, 2011

.http://www.sec.gov/Archives/edgar/data/838879/999999999714011663/filename1.pdf

****************************************************************

Dominion Minerals Corporation.


10-12G Documents Registration of securities [Section 12(g)]
Acc-no: 0001213900-14-007607 (34 Act) Size: 1 MB 2014-10-31 000-52696
141184196

REVOKED Documents Commission order revoking Exchange Act registration [Section 12(j)]
Acc-no: 9999999997-12-014580 (34 Act) Size: 24 KB 2012-11-16 000-52696
121210317

http://www.sec.gov/cgi-bin/browse-edgar?company=Dominion+Minerals+Corp&match=&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany&Find=Search

The Securities and Exchange Commission (“Commission”) deems it necessary and
appropriate
for the protection of investors to accept the Offer of Settlement submitted by
Dominion Minerals Corp.

1.
DMNM
(CIK No.
1402747
) is
a void
Delaware
corporation
located in
New York, New York
with a class of securities registere
d with the Commission under
Exchange Act Section 12.
As of
September 25, 2012
, the
common stock
of
DMNM
(symbol
DMNM
)
was
quoted on OTC Link (formerly "Pink Sheets") operated by OTC
Markets Inc.
, had
seven
market makers, and was eligible for the
“piggybac
k”
exception
of Exchange Act Rule 15c2
-
11(f)(3).
2.
DMNM
has failed to comply with Exchange Act Section 13(a) and Rules
13a
-
1 and 13a
-
13 thereunder because it has not filed any periodic reports with the
Commission since the period ended
March 31, 2009

http://www.sec.gov/Archives/edgar/data/1402747/999999999712014580/filename1.pdf



****************************************************************

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113731493

5/16/15

A new person to the board posted below stated:in this post below..

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113730276

"There are no 5 billion shares to be held tight. They've been gone for a year."

They are not gone forever.Please take the time to read ALL my analysis on how revoked shares can be re-instated.

"The SEC will tell you that IS a fact."

The SEC tells you that all you have to do is file your past due annual reports..In the case of Radient it is 2012 and 2013..Radient went void on March 1, 2014 and was insolvent in 2014.The 2014 and 2015 annual reports were filed by AMDL Diagnostics Inc.


" Distraction from sales? What sales. Radient isn't selling anything. The company shut the doors."

true, radient isn't selling nada.Its wholly owned subsidiary is selling Onko-Sure in India,Korea, Taiwan, etc..The monies collected are being used to pay down the small accounts payable debt...All this included in the analysis..Please take the time to read..

"They are void, insolvent, and revoked. Once off patent the agreements were null per the filings."

You are wrong about your last opinion. here is a elementary link to help one understand what a non-disclosure in an agreement means...The Provista Diagnostics agreement is still in force along with the Global Cancer Diagnostics and Uni-Pharma agreements before the 2013 agreements pertaining to the patents. Even though those agreements are expired, they still have a 5 year non-disclosure clause..Consult an attorney or read the elementary link on patents..

http://www.wikihow.com/Protect-Your-Ideas-Without-a-Patent

"4 Hire a lawyer to make a non-disclosure agreement. A patent lawyer will be able to offer the best contract protection, by making a document that people are required to sign before you discuss your idea."

Keep in mind that non-disclosure agreements typically come with a set duration of a few months to 5 years. Make sure you are ready to use your idea when you begin talking about it.




" Reverse merger you say? Well some have been saying that for 4 or 5 years and held all the way til their shares were worthless and revoked."

True it has been 5 years, that is what a five year plan is all about...Mac came along to restructure Radient/AMDL...Not to sell a placenta skin cream..lol But the future of Dr-70 along with Provista bio-markers... Here are two elementary links on what a subsidiary can do while the parent is insolvent before it it is reborn again.....

Radient is temporarily insolvent..AMDL Diagnostics a wholly owned subsidiary is still active and selling Onko-Sure you understand....

http://smallbusiness.chron.com/happens-subsidiary-company-parent-company-becomes-insolvent-25450.html

http://www.ehow.com/info_12328436_happens-subsidiary-company-parent-company-becomes-insolvent.html

Even though Onko-Sure is off patentd oesn't mean they can't sell it..AS long as they have their manufacturere and distributor in place, it doesn't matter..included inm y analysis, there is agreements with provista DIAgnostics and Uni-pharma still in force, along witht he re-engaged agreement with Global CAncer DIagnostics..ALL have 5 year non-disclosure clauses included..

http://www.dailyfinance.com/2011/02/27/top-selling-drugs-are-about-to-lose-patent-protection-ready/

Here is another link to show how non-confidentiality clauses are enforced during and after an agreement is expired/terminated..Radient and provista/Uni-Pharma and Global Cancer DX have a 5 year expiration in all their agreements.

"During the term of this agreement and three years thereafter, Acme shall keep the Information confidential."

http://www.adamsdrafting.com/duration-confidentiality-agreements/

Radient Is Being Restructured by A Reverse Merger


Part 1 April 20, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112893006


Part 2 April 21, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112930694


Part 3 April 22, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112973321

Part 4 April 23, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113014648

Part 5 April 24, 2015 Rebuttals

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113056841

Part 6 April 25, 2015 Rebuttals

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113091753

Conclusion: April 26, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113104999

Uni-Pharma Part 1 April 27, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113119285

Uni-Pharma Part 2 April 28, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113155567

Uni-Pharma Part 3 - Global Cancer Diagnostics Part 1
April 29, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113192928

GCDX and Uni-Pharma April 30, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113228108

Uni-Pharma Conlusion May 1, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113264286



****************************************************************

5/15/15

Wrong..AMDL Diagnostics Inc. is not and will not be run by the aussies..AMDL Diagnostics Inc. is a separate entity run by William and mac..Nice spin anyhoo..lol...Charter has over 400 web site domains..In your opinion he must be running 400 companies...Sure lol..FYI AMDL Australia is only a distributor in India and not going to run the company when the reverse merger is finalized...All the monies are going to AMDL Diagnostics Inc. to pay down the Accounts payable..Send 10 dollars to Delaware....The AMDL Diagnostics Inc. has been in good standing without interuption since 2009...imo

He doesn't own amdl.com


Radient Pharmaceuticals Corporation *

www.amdl.com - Proxy - Highlight

Radient Pharmaceuticals Asks DHS Holding Co. To Retract News Release Saying It Will Enter Into Talks With Radient Pharmaceuticals Corporation » More.


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113540686



AMDL Diagnostics Inc. and SRL Diagnostics Onko-sure – a blood test to screen 13 types of cancers
May 15, 2015

Elite Wellness Package


Onkosure

http://www.srlworld.com/wellness/content/160/niche-wellness-test.html

https://www.linkedin.com/pub/ikrar-khan/36/632/5a4?trk=pub-pbmap


Onko-sure – a blood test to screen 13 types of cancers
Admin Feb 01, 2013

http://www.thehealthsite.com/news/onko-sure-a-blood-test-to-screen-13-types-of-cancers/


Onkosure by SRL Diagnostics - Single blood test to screen 13 types of cancers
Sep 20th, 2011


http://www.srlworld.com/content/78/press-release/27.html

http://www.srlworld.com/media/1/press-releases.html

UPDATE ON METROPOLIS WEB SITE


Cancer 8

Cancer 8 is an initiative by Metropolis to bring awareness about cancer detection. Cancer 8, introduced by Metropolis in India, is a simple, non-invasive and FDA cleared in vitro diagnostic (IVD) blood-marker test known as Onko-Sure®. Detect cancer early with a simple blood test

http://www.metropolisindia.com/patients

http://www.metropolisindia.com/patients/cancer-eight




****************************************************************

Thank you Jim..We saw that list last month...

The newcomer to this Board, Get SeriousOK asked...."why is radient on the list"...

Here is why...

Provista Diagnostics Inc.To Acquire Radient Pharmaceuticals

http://www.pharmpro.com/news/2010/07/radient-pharmaceuticals-acquire-provista-diagnostics-inc

Provista to go public with breast, lung cancer testing technology

http://www.bizjournals.com/phoenix/print-edition/2011/12/30/provista-to-go-public-with-breast.html

http://www.bizjournals.com/profiles/company/us/az/scottsdale/provista_diagnostics/3235221

http://globalcancerdx.com/About.html

http://provistadx.com/

***************************************************************

Thresher a/k/a Gold/Get Serious/ V_G asked:

thresherfailed on The Many Veils Of Radient Pharmaceuticals (Onko-Sure DR-70) guardiangel, when are you going to update this ...

We have updated at your request..You will find it in our Facebook Page... We also answered the CIT and a new question...

Who is Operating AMDL Diagnostics, Inc?

William and Don, Brown and White or mac and Akio



http://www.sec.gov/Archives/edgar/data/838879/000114420414027804/v377522_8k.htm

On September 3, 2013 we posted...Within a month two of our predictions came true..The third prediction is now coming to fruition you understand....

The Many Veils Of Radient Pharmaceuticals (Onko-Sure DR-70)

I will provide a more storied version of this article, but for now here are some links to contemplate you understand.

Equivilant to Radient's CIT Technology:

$500 million dollar buyout!

ANSWER..On Facebook Page...ahoooooooooooooooooooooooo

Guess which one of these companies are involved with Radient behind the scenes?

Arizona State University, Mayo Clinic, Mayo Collaborative Services, etc...

Provista Diagnostics Licenses Biomarker Technologies Developed at Arizona State University
October 25, 2013

SCOTTSDALE, Arizona, October 25, 2013 - Provista Diagnostics, Inc., a leading molecular diagnostics company focused on developing and commercializing proprietary diagnostic, prognostic and predictive tests for cancers affecting women, has licensed a series of biomarker technologies developed by researchers at the Biodesign Institute of Arizona State University. Provista will evaluate the technologies for use in the early detection of breast cancer, ovarian cancer and HPV.

http://www.provistadx.com/home/news-and-events

What's going on in Arizona?

ASU Spinout HealthTell Raises $4 million in New Funding for Innovative Cancer Tests

Awarded first grant and research incentive
November 01, 2013


http://www.provistadx.com/home/news-and-events

Just a quick tidbit for now. Stay tuned to see how Radient Pharmaceuticals is controlling the Global Cancer Diagnostics market behind the scenes, and what the few remaining shareholders will get as a cash distribution / shares of the new company from the upcoming merger!



http://seekingalpha.com/user/8702411/instablog

Tags: RXPC, rumored
Sep 03 9:48 AM |
Link
|
8 Comments





Living Stated:

"AMDL has no shareholders.

it is a private DE company ".

"charter does not control what's left over,"

GOODBYE REXACT SCIENCE...ahooololoooololooooooooooooooo

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113536464

http://www.darkdaily.com/cheap-fast-accurate-home-colon-cancer-test-joins-growing-list-of-diagnostic-tests-shifting-from-medical-laboratories-to-homes-520#axzz2TplS0qfP



Living yes you are correct. AMDL Diagnostics Inc. is a wholly owned subsidiary of Radient. It controls the re-engaged agreements with Uni-Pharma and Global Diagnostics Inc. and the agreement with Provista Diagnostics to research, develop, and commercialize DR-70 in over 13 types of cancer detections.

Where your opinion is wrong and misleading is the aussies do not control radient..The current president Mac and the secretary, Akio are the only officers that can re establish radient in Delaware and with the SEC..Akio has all the past annual reports.

Email mac and see if he can affirm the re-engaged agreements...Dead end....lol AMDL Diagnostics Inc. is a PRIVATE company..Smart move by mac and Akio planned back in 2009 when they set up AMDL DX for the planned reverse merger LOI 2010 with provista Diagnostics..

Here is a link ON AMDL and the re-engaged agreements with Uni-Pharma and GCDX after DR_70 went off patenet..Enjoy the reading from our analysis..


Radient Is Being Restructured by A Reverse Merger


Part 1 April 20, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112893006


Part 2 April 21, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112930694


Part 3 April 22, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112973321

Part 4 April 23, 2015

***********************************************************

All of the lenders had limitations to the amount of shares they could hold depending on the outstanding shares. That is why the conversions were done over a long period. Radient would periodically add shares to the float. The lenders would then convert up to their limitations and the angel investors would start their buying from the leftovers.. Sometimes slowly/creeping or on large volume days....The large volume days were the angel investors purchasing shares. On July 5, 2013 we announced that we were going to buy 94 million shares. We made this announcement on another board. Our announcement was 10 minutes before the closing bell. The volume was 34 million and the pps was .0001/.00005. Right after our buy, an angel investor purchased 144 million shares, bringing the volume at the end of the day to509,271,900. The following trade day was Monday July 8. As you can see, the volume was 150,422,200. The following day it was 59,748,300. This would give the next angel investor around 105 million shares. The lenders would not be in a position to purchase this amount of shares in those 3 trading days. That would have placed them over their respective limitations(blockers). The large volume days in 2012,2013, and 2014, were angel investors. The angel investors own around 3 billion shares, 65 per cent of the 4.5 billion outstanding. That would only take 13 angel investors at 224 million holdings keeping them under the 4.99 per cent, so they would not have to file minority ownership.

On July 5, 2013 when we announced our 94 million buy, either the angel investor was monitoring the board or someone who is connected to them that is always monitoring the boards and then contacted them...That was our way of finding out if they would be spooked and buy..By announcing our intentions...It worked..Now that was entertainment you understand..Funny too...ahoooooooooo

.

Jul 5, 2013 0.00 0.00 0.00 0.00 509,371,900


The following two trading days, another angel investor came along to purchase the remeining shares in the float. The pps of .0001/.00005 was never offered again.

Jul 9, 2013 0.00 0.00 0.00 0.00 59,748,300 0.00
Jul 8, 2013 0.00 0.00 0.00 0.00 150,432,200 0.00

The next angel investor added 105 million shares on July 8 and July 9.

http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=198


***************************************************************

B_B This is why there was no bankruptcy.Right after this agreement was signed, All of the lenders starting converting their shares.


As a condition to the exercise of the Warrants, we agreed that following the date of the Agreement and through and including 5:00 p.m. (EDT) on August 31, 2012, we will not file in any U.S. Bankruptcy Court a voluntary petition for reorganization under Chapter 11 of Title 11 of the United States Code or seek to liquidate under Chapter 7 of such Code. Additionally, each of the 2011 Noteholders, severally and not jointly, agreed to forebear from exercising any of their rights and remedies, whether at law or in equity, against us and our current and former directors and officers for a period that shall not exceed the earlier to occur of (i) August 31, 2012, or (ii) a breach by us of any of our other covenants and agreements contained in the prior agreements with the 2011 Noteholders or in the current Agreement, including, without limitation, our commitment to file with the SEC our 2011 Form 10-K by June 30, 2012 and our March 31, 2012 Form 10-Q by July 15, 2012.

Radient did file their 10-K by June 29,2012 and did not file bankrupcy as agreed to. The only filing that was not filed was the 2012 10-Q...Everything after December 31, 2011 is a mystery for a reason. Starting in May 2012, the lenders converted their shares over a two years period. They were limited to 9.99, less than 5 percent and 1 percent. There were two lenders limited to 9.99% or less, one lender less than 5% and four at 1.00%..

http://www.sec.gov/Archives/edgar/data/838879/000114420412037312/0001144204-12-037312-index.htm

*****************************************************************
Gold seeker Stated:

Bascally, every 2012 8K said Radient was Insolvent.

The definition of Insolvent is "unable to pay obligations." Almost every 8K in 2012 stated that Radient was unable to pay their obligations. How could anyone read the 2012 8K's and think Radient was going to survive, let alone complete a merger?

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113391488

Your Webster's definition is correct about the definition of insolvency. Basically it is the same but it wasn't. The company survived for two years and then stated it was insolvent in April 2014. It became insolvent on March 1, 2014 for not filing 2012 and 2013 annual reports in Delaware..While they were stating in 8-K's in 2012 they did state they were working on licensing agreements to pay down Accounts payable. The first step to pay down the Accounts payable of $966,000 was the agreement to offer stock to the lawyers in lieu to the $300,000 owed. That brings the AP to $666,000. We do agree with you that Radient did become quasi-insolvent the year ending December 31, 2012. The agreement with Global Cancer Diagnostics according to the royalty payment was to begin on January 1, 2013. The company stated they were going to engage in a new agreement with GCDX..That agreement was the same as the agreement AMDL Diagnostics Inc made with Uni-Pharma. Therefore, in order to keep Radient insolvent as we both agree to, the royalty/License fees were channeled to AMDL Diagnostics Inc. The monies from these agreements were used to pay down the $666,000 Accounts payable. Since Radient was insolvent in 2013, they would have to file an annual report to re-instate the corporation in Delaware, but since there was no monies collected,no payroll, no payments to creditors, the annual report wouldn't be costly since no audit is needed...The same for 2014.. Only two months of no operations when the corporation went void on March 1, 2014. That is why in 2013, the Uni-Pharma was between AMDL Diagnostics.Inc. Since AMDL Diagnostics Inc can operate as a private concern, the public has no knowledge what was going on in 2013..Similiar to 2012, since radient didn't file its 10-Q's or 10-K. BASICALLY, Radient has been an insolvent company since January 1, 2013. BASICALLY, a public shell up to July 3, 2014. The Merger plan has been successful. All the lenders are holding their shares. The Angel investors are holding their shares. The Longs are holding their shares, and others are being entertained you understand..lol

When you posted the 8-K's you forgot this one in 2012. Who do you think is going to merge with Radient? Global Cancer Diagnostics or Provista Diagnostics? Or both?



On July 13, 2012, we entered into a license agreement with Global Cancer Diagnostics, Inc. ("GCDx") in order to commercialize certain of our intellectual property in the form of a Lung Cancer test; the intellectual property at issue is specified in the Agreement and is herein referred to as the Licensed Products. Under the Agreement,


Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the agreements, which subsequent information may or may not be fully reflected in public disclosures by us.

http://www.sec.gov/Archives/edgar/data/838879/000114420412039787/v318772_8k.htm

BRISTOL INVESTMENT FUND LTD

Filing Date
2012-02-15


9.Aggregate Amount Beneficially Owned by Each Reporting Person
897,621 shares of common stock*
*plus shares underlying $3,056,006.67 of principal amount of convertible instruments and warrants to purchase 2,500,238,718 shares of common stock, neither of which may be converted into more than 1% of Common Stock

http://www.sec.gov/Archives/edgar/data/838879/000101968712000550/bristolradient_13ga2.htm


*****************************************************************


As previously disclosed in our recent filings, we have been experiencing severe working capital shortages. In addition, substantially all of the holders of approximately $14.0 million of our notes and redeemable preferred shares (the “2011 Noteholders”) had previously declared defaults and demanded repayment of these obligations, which we were unable to pay.



On May 17, 2012, we completed an Agreement with the 2011 Noteholders, severally and not jointly, for the exercise of an aggregate of $150,000 worth of our Series A Common Stock Purchase Warrants at an exercise price of $0.02619 per share. The proceeds received from such Warrant exercise, shall be used solely and exclusively to enable us to keep our Registration Statement on Form S-1 filed under the Securities Act of 1933, as amended, which the Securities and Exchange Commission declared effective on February 14, 2012, current and maintain compliance with our reporting requirements under the Securities Exchange Act of 1934, as amended.



As a condition to the exercise of the Warrants, we agreed that following the date of the Agreement and through and including 5:00 p.m. (EDT) on August 31, 2012, we will not file in any U.S. Bankruptcy Court a voluntary petition for reorganization under Chapter 11 of Title 11 of the United States Code or seek to liquidate under Chapter 7 of such Code. Additionally, each of the 2011 Noteholders, severally and not jointly, agreed to forebear from exercising any of their rights and remedies, whether at law or in equity, against us and our current and former directors and officers for a period that shall not exceed the earlier to occur of (i) August 31, 2012, or (ii) a breach by us of any of our other covenants and agreements contained in the prior agreements with the 2011 Noteholders or in the current Agreement, including, without limitation, our commitment to file with the SEC our 2011 Form 10-K by June 30, 2012 and our March 31, 2012 Form 10-Q by July 15, 2012. The 2011 Noteholders further agreed that in the absence of a further breach of the terms of the Agreement or any of the other agreements between us and the 2011 Noteholders, that each of the previously issued default notices shall be deemed to be withdrawn ab initio upon execution of the Agreement.



Additionally, as part of the Agreement and in order to provide for payment of past due legal fees, we agreed to issue to our legal counsel, Hunter Taubman Weiss LLP, a $300,000 unsecured convertible 4% Company note payable on April 30, 2015, which shall (i) accrue interest at the annual rate of 4% per annum, (ii) be convertible into our Common Stock at a fixed conversion price of $0.01 per share, (iii) be subject to prepayment at the option of the Company, (iv) contain full ratchet and other customary anti-dilution protection, and (v) not be subject to any mandatory installment or other mandatory prepayment provisions prior to the April 30, 2015 maturity date.

Additionally, as part of the Agreement and in order to provide for payment of past due legal fees, we agreed to issue to our legal counsel, Hunter Taubman Weiss LLP, a $300,000 unsecured convertible 4% Company note payable on April 30, 2015, which shall (i) accrue interest at the annual rate of 4% per annum, (ii) be convertible into our Common Stock at a fixed conversion price of $0.01 per share, (iii) be subject to prepayment at the option of the Company, (iv) contain full ratchet and other customary anti-dilution protection, and (v) not be subject to any mandatory installment or other mandatory prepayment provisions prior to the April 30, 2015 maturity date.


http://www.sec.gov/Archives/edgar/data/838879/000114420412030793/v313941_8k.htm

****************************************************************
The aussies are now out of the picture..The temps are gone..They will however be a part of the overseas operations..Possibly distributors in Australia and New Zealand, and India..We will see what William has in mind you understand...Wolf


http://finder.cox.net/main?InterceptSource=0&ClientLocation=us&ParticipantID=96e687opkbv4scrood8k84drs6gw5duf&FailureMode=1&SearchQuery=&FailedURI=http%3A%2F%2Fradient-diagnostics.com%2F&AddInType=4&Version=2.1.8-1.90base&Referer=&Implementation=0&method=GET

DC The agreement between AMDL Diagnostics Inc. and Global Cancer Diagnostics Inc. gave GCDX to sell the Lung Cancer Test worldwide..That included canada. We now know the new engaged agreement was not the same as the Uni-Pharma agreement..The GCDX agreement is still in force until the merger..You understand..Underdawg


****************************************************************

The Lendrs converted and own 25 to 29 percent of Radient Outstanding Shares.


*St George Investments LLC

Filing Date
2011-11-17

ITEM 5:

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following box: q

http://www.sec.gov/Archives/edgar/data/838879/000136456011000007/stgeo_sc13g.htm



*ALPHA CAPITAL ANSTALT

Filing Date
2012-01-05

9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -

30,189,009 shares of Common Stock

Pursuant to the terms of the November 28, 2011 agreement modifying the Final Settlement Agreement, the convertibility of the notes issued to Alpha Capital Anstalt, the issuance of Settlement Shares and the convertibility and exercisability of all convertible and exercisable instruments of the Company held by Alpha Capital Anstalt is limited if, upon issuance, conversion or exercise thereof, Alpha Capital Anstalt or any of its affiliates would beneficially own more than 2.9% of the Company’s common stock.

http://www.sec.gov/Archives/edgar/data/838879/000121390012000035/sc13g0112a2alpha_radient.htm

*KINGSBROOK PARTNERS LP

Filing Date
2012-02-13

Pursuant to the terms of the Reported Securities, the Kingsbrook Fund cannot convert or exercise, as applicable, any of the Reported Securities unless the Reporting Persons would not beneficially own, immediately after any such conversion or exercise, as applicable, more than 1.0% of the outstanding shares of Common Stock (the “Blocker”).

http://www.sec.gov/Archives/edgar/data/838879/000090266412000289/p12-0319sc13ga.htm

*Cranshire Capital, L.P.

Filing Date
2012-02-13

9)Aggregate amount beneficially owned by each reporting person

10,506,177

The foregoing excludes (I) 850,081,168 shares of Common Stock issuable upon exercise of a Series A Warrant held by Cranshire Capital (the “Cranshire Series A Warrant”) because the Cranshire Series A Warrant contains a blocker provision under which the holder thereof does not have the right to exercise the Cranshire Series A Warrant to the extent (but only to the extent) that
such exercise would result in beneficial ownership by the holder thereof or any of its affiliates, of more than 1.0% of the Common Stock,

http://www.sec.gov/Archives/edgar/data/838879/000119312512056392/d299617dsc13ga.htm

*CAPITAL VENTURES INTERNATIONAL

Filing Date
2012-02-14

(9)Aggregate Amount Beneficially Owned by Each Reporting Person
0
http://www.sec.gov/Archives/edgar/data/838879/000110465912009529/a12-4562_12sc13ga.htm



*Iroquois Capital Management, LLC


Filing Date
2012-02-14


9.Aggregate Amount Beneficially Owned by Each Reporting Person

10,458,877

http://www.sec.gov/Archives/edgar/data/838879/000119312512059770/d301526dsc13ga.htm

*Ironridge Global IV, Ltd.

Filing Date
2012-02-14

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

q Rule 13d-1(b)

þ Rule 13d-1(c)

q Rule 13d-1(d)

ITEM 5: Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following box: þ

http://www.sec.gov/Archives/edgar/data/838879/000114420412008772/v302589_sc13ga.htm

*BRISTOL INVESTMENT FUND LTD

Filing Date
2012-02-15

9. Aggregate Amount Beneficially Owned by Each Reporting Person
897,621 shares of common stock*
*plus shares underlying $3,056,006.67 of principal amount of convertible instruments and warrants to purchase 2,500,238,718 shares of common stock, neither of which may be converted into more than 1% of Common Stock


http://www.sec.gov/Archives/edgar/data/838879/000101968712000550/bristolradient_13ga2.htm

*WHALEHAVEN CAPITAL FUND LTD

Filing Date
2012-05-21

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -

6,496,317 shares of Common Stock

The aggregate amount in Row 9 represents the maximum amount of shares that Whalehaven Capital Fund Limited can beneficially control under a contractually stipulated 9.99% ownership restriction.

*ALPHA CAPITAL ANSTALT


Filing Date
2012-05-21

9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -

6,496,317 shares of Common Stock

The aggregate amount in Row 9 represents the maximum amount of shares that Alpha Capital Anstalt can beneficially control under a contractually stipulated 9.99% ownership restriction.

http://www.sec.gov/Archives/edgar/data/838879/000121390012002926/sc13g052112alpha_radient.htm


The Lendrs converted and own 25 to 29 percent of Radient Outstanding Shares.

Alpha 9.99%
Whalehaven 9.99%
St.George Less than 5.00%
Kingsbrook 1.00%
Iroquois 1.00%
Bristol 1.00%
Cranshire 1.00%

CAPITAL VENTURES INTERNATIONAL

Filing Date
2010-04-30

(9)Aggregate Amount Beneficially Owned by Each Reporting Person
1,473,678

http://www.sec.gov/Archives/edgar/data/838879/000083887910000003/xslFormDX01/primary_doc.xml

CAPITAL VENTURES INTERNATIONAL

(9)Aggregate Amount Beneficially Owned by Each Reporting Person
2,216,588

http://www.sec.gov/Archives/edgar/data/838879/000110465911006827/a11-5461_7sc13ga.htm

CAPITAL VENTURES INTERNATIONAL


Filing Date
2012-02-14

(9)Aggregate Amount Beneficially Owned by Each Reporting Person
0


http://www.sec.gov/Archives/edgar/data/838879/000110465912009529/a12-4562_12sc13ga.htm

*****************************************************************

We will show how the Lenders converted and accumulated their limitation of 25 per cent of the RXPC outstanding shares along with the Provista/GCDX Angel investors 65 per cent of the outstanding and the 10 per cent of a few longs. Radient placed 4,509,000,000 shares into the float and the 491 million are for the Attorney firm that will be able to convert $300,000 of debt for around a holding of 34 million shares. The remaining shares will be for Mac, Akio,etc..The 1.8 million dollars of share based funds...Mac and Akio aren't going anywhere. Tomorrow we will break down the 25 per cent owned by the 2011 lenders 9.99 per cent,collectively, John Fife and St. George, 10 per cent, Capital Inventures 4.99 per cent. etc... Stay tuned

Gold Seeker Stated:

"Radient was insolvent in December 2012."

"That is when they disclosed that they owed $900,000 for operational costs (vendors, suppliers, leases) and had no way to pay. That is the definition of "insolvent."

Even if UNI still paid Radient the $200,000 per year royalty fee after the last patent expired, it would not have saved Radient from death.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113268667

Gold, You stated that Radient was insolvent in December 2012. When we saw that post, we knew that it couldn't be true..We did give you the benefit of the doubt and did some research. We checked all the 8-K's for the year 2012 and could not find the disclosure you stated or any language about "Radient being insolvent. We thought maybe you were referring to 2011 as well, but did not find it there, as well.

Here is what we found in 2012..

From an operational perspective, we continue to sell and ship Onko-Sure test kits to the following territories: Korea, Turkey, Taiwan, India, Vietnam, and the U.S. Despite significant financial hardship, the Company continues to maintain its operations in Tustin, relying on selective former employees that continue to work as consultants to the Company. We are also engaged in business discussions with other companies seeking to license Onko-Sure for various international territories. These licensing agreements, if completed, are anticipated to provide the Company with the funds necessary to regain compliance with our public filing requirements and to begin to pay down various overdue accounts payable. There can be no guarantee that any new licensing transactions will be completed.

As of October 3, 2012, we had 3,235,210,154 shares of common stock issued and outstanding.

http://www.sec.gov/Archives/edgar/data/838879/000114420412054967/v325211_8ka.htm

http://www.sec.gov/cgi-bin/browse-edgar?company=Radient+Pharmaceuticals&owner=exclude&action=getcompany

This is the first 8-K in 2013 and the company is still selling Onko-Sure in territories specified within the 8-K..Still no mention of insolvency.


From an operational perspective, with appropriate capital, we can continue to sell and ship Onko-Sure® test kits to the following territories: Korea, Turkey, Taiwan, India, Vietnam, and the U.S. Despite significant financial hardship, we continue to maintain our offices and FDA approved manufacturing facilities in Tustin, California, relying on selective former employees that continue to work as consultants. We are also engaged in business discussions with other companies seeking to license or purchase Onko-Sure for various domestic and international territories, although we have not entered into any formal agreements at this time. We are hopeful that if we can complete a sufficient number of these licensing and sales agreements, we will have enough capital to regain compliance with our public filing requirements and to begin to pay down various overdue accounts payable. These agreements may also allow us to restructure or convert to equity our existing notes payable in order to significantly reduce or eliminate a majority of the liabilities on our balance sheet. There can be no guarantee that any new licensing, purchase or restructuring transactions will be completed or that they will provide sufficient capital to carry out our plans.

As of June 10th 2013, we had approximately 4,508,746,417 shares of common stock issued and outstanding.

http://www.sec.gov/Archives/edgar/data/838879/000121390013003078/f8k061113_radientpharm.htm

This is the only SEC filing we found stating that radient was insolvent. This is from May 6, 2013. Radient was NOT insolvent in December 2012 as you claim. We knew this wasn't true because Radient entered into an agreement with Global Cancer Diagnostics in October 2012 and was receiving licensing fees and royalty fees. In June 2013 AMDL Diagnostics a wholly owned subsidiary entered into an agreement with Uni-Pharma and received royalties as you stated in your post, except it was $100,000 and not $200,000 as you stated. The monies from Uni-Pharma were being collected by AMDL Diagnostics Inc. and were used to pay down the Radient debt. The monies from the India Government program and SRL Diagnostics and Metropolis are also being collected by AMDL.

Despite significant financial hardship, the Company continues to maintain its offices and manufacturing facilities in Tustin, California, relying on selective former employees that continue to work as consultants. The Company is currently insolvent and the new Board of Directors and the new senior management of the Company have been appointed to attempt to restructure the Company. There can be no guarantee that any new business or restructuring transactions will be completed or that they will provide sufficient capital to carry out the Company's business.

On April 15, 2014, the Company executed an Offer of Settlement with the Securities and Exchange Commission (“Commission”) pursuant to Section 12(j) of the Securities Exchange Act of 1934, revoking the registration of the Company’s securities.

http://www.sec.gov/Archives/edgar/data/838879/000114420414027804/v377522_8k.htm


Gold Seeker also Stated:

"Radient revoked share registration to hide revenues?"

Instead of filing financials, Radient revoked share registration, because filing financials would reveal revenues that Radient wants to hide?

Radient said "we are insolvent" in an SEC filing when in truth they were making $$$ millions selling onko-sure in India?

If true, RXPC shareholders think this is good?"

Fascinating.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113368735

Gold, What we referring to is that Radient didn't file their 2012, 2013 and 2014 annual reports up to March 1, 2014.Radient became insolvent on March 1, 2014 when it became a Void Delaware Corporation.AMDL Diagnostics Inc has all the assets in their corporation along with the agreements. They are also paying down the debt. The Radient Corporation is insolvent but AMDL Diagnostics Inc. is still operation as the company has stated in their PR;s and SEC Filings since 2009 when the Corporation was formed.. The President of AMDL Diagnostics Inc. is Mac and the Secretary is Akio..They are also the officers of Radient. According to the May 6, 2013 8-K they did not resign as officers of radient. Mac is still the President and Akio is the Secretary..Here is the proof..SEC Filings are Facts you understand..Also you mentioned in a post that Mac couldn't be found.Mac is not hiding, he can be found in the AMDL Dianostics and the Radient Corporation as the President of both Corporations.



On April 30, 2014, the Board of Directors of the Company including Mr. Douglas C. MacLellan and Mr. Michael Christiansen appointed the following persons to the Company's Board: Mr. Jim Green, Mr. Darren Brown, Mr. Bill White and Mr. Dennis Charter. Additionally, the following persons will be appointed to the following positions:

Immediately following these appointments, Mr. MacLellan resigned as Chairman and CEO and Mr. Christiansen resigned as the Company's only other board member. Separately, Mr. Akio Ariura the Company's previous CFO and COO, resigned from both positions on April 28, 2014. None of these directors or officers resigned as a result of a disagreement with the Company.

http://www.sec.gov/Archives/edgar/data/838879/000114420414027804/v377522_8k.htm

Here is the SEC 8-K showing Mac as President and Akio as Secretary..Interesting they performed a Power of attorney in case one passed away..It was done on July 9, 2012 Four days prior to the Global Cancer Diagnostics agreement..


Signature Title Date

/s/ Douglas C. MacLellan President, Chief Executive Officer, and Director June 29, 2012
DOUGLAS C. MACLELLAN (Principal Executive Officer)

/s/ Akio Ariura Chief Operating Officer, Chief Financial Officer June 29, 2012
AKIO ARIURA and Secretary (Principal Financial Officer and Principal Accounting Officer)

/s/ Michael Boswell Director June 29, 2012
MICHAEL BOSWELL

Filing Date
2012-07-09

http://www.sec.gov/Archives/edgar/data/838879/000114420412038691/0001144204-12-038691-index.htm

http://www.sec.gov/Archives/edgar/data/838879/000114420412037457/v317455_10ka.htm

The Power of attorney was signed on June 29, 2012 and posted on July 9, 2012..This is when Global Cancer Diagnostics and provista Diagnostics and the Angel Investors began their Creeping takeover of 65 per cent of the RXPC shares. Check out the volume the day before the Power of Attorney was signed and the day after the 10-K was filed. The Agreement between Radient and GCDX wasn't signed until July 13, 2012 and the 8-K was released on July 17, 2012... No retail or what you call"ebabies" even touched the stock.. This is because their weren't no "ebabies" buying the stock over the 2 year period, only Provista Angel Investors, Lenders converting, and a few investors including Dc and Guardianagel

Jul 18, 2012 0.00 0.00 0.00 0.00 28,268,400 0.00
Jul 17, 2012 0.00 0.00 0.00 0.00 22,938,000 0.00
Jul 16, 2012 0.00 0.00 0.00 0.00 36,264,300 0.00..

Jul 13, 2012 0.00 0.00 0.00 0.00 25,656,000 0.00
Jul 12, 2012 0.00 0.00 0.00 0.00 32,886,000 0.00
Jul 11, 2012 0.00 0.00 0.00 0.00 94,461,400 0.00
Jul 10, 2012 0.00 0.00 0.00 0.00 524,879,000 0.00
Jul 9, 2012 0.00 0.00 0.00 0.00 30,715,900 0.00
Jul 6, 2012 0.00 0.00 0.00 0.00 8,430,000 0.00
Jul 5, 2012 0.00 0.00 0.00 0.00 18,487,000 0.00
Jul 4, 2012 0.00 0.00 0.00 0.00 0 0.00
Jul 3, 2012 0.00 0.00 0.00 0.00 23,972,900 0.00
Jul 2, 2012 0.00 0.00 0.00 0.00 166,400,100 0.00
Jun 29, 2012 0.00 0.00 0.00 0.00 64,732,200 0.00
Jun 28, 2012 0.00 0.00 0.00 0.00 182,674,700 0.00


http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=462

Mac and Akio will have the power to re-instate Radient Pharmaceuticals..Here is the Delaware Corporation Law.

may at any time procure an extension, restoration, renewal or revival of its charter, together with all the rights, franchises, privileges and immunities and subject to all of its duties, debts, and liabilities which had been secured or imposed by its original charter and all amendments thereto by filing with the Secretary of State a certificate of its last acting president and secretary or treasurer, or other officers to be elected as hereinafter provided, duly sworn or affirmed to by such officers before any person authorized by the laws of this State to administer oaths or affirmations, which certificate shall set forth:

If the last president and secretary or treasurer or the officers performing the functions of said offices or any of them of any such corporation so desiring to renew or revive its charter should be dead at the time of such renewal or should refuse or neglect to act with respect thereto as provided in the first paragraph of this section, the directors of such corporation or the survivors of them,....

http://delcode.delaware.gov/sessionlaws/ga105/chp147.shtml

Here is the breakdown of the Lender conversions and the Provista/GCDX Angel investors and a few longs.

*The Lenders started converting..6 Trading days totaling 1.226 Billion shares of volume.

May 24, 2012-June 1, 2012

http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=528

(Lender conversions along with Angel investors...5 Trading days and 584 Million shares of volume.

June 13, 2012-June 25, 2012

http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=528

*Lender conversions and Angel Investors..619 million shares of volume in 2 trading days.

June 28,2012-July 2,2012

http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=462

*Lender conversions and Angel investors..1.2 Billion shares of volume in 4 trading days.

September 20, 2012-October 1, 2012

http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=462

The 2012 conversions and accumulation volume totaled 4 billion in 20 trading days. That is an accumulation of 2 Billion shares being held by Lenders, Angel investors, and a few long investors.


*Lenders conversions and Angel investors.
1.3 billion volume in 6 trading days.

February 1, 2013-March 28, 2013

http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=330

*Lender conversions and angel investors.

622 million of volume in 3 days of trading.

April 4, 2013-April 26, 2013

http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=264

*Lender conversions and angel investors.

760 million shares of volume in 4 trading days.

July 3, 2013-July 9, 2013

http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=198

Total volume in 2013 was 2.7 billion shares in 13 trading days. 1.35 billion shares accumulated.


*Angel investors.

780 million in volume in 2 trading days.

February 24, 2014-February 25, 2014

http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=66

*Angel investors.

756 million shares of volume in 4 trading days.

March 20,2014-March 27,2014

http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=66

*Angel investors

745 million shares of volume in 2 days of trading.

May 6, 2014-May 7,2014

http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=0

2014 total volume 2.28 billion shares in 2 trading days. accumulation and holding 1.14 billion shares.


Total 2012,2013,and 2014...9 billion total volume in 35 trading days and 4.5 billion shares held by Lenders, Angel investors, and Longs...The lenders holding 25 per cent, angel investors 65 per cent and the longs 10 percent...During the time of the accumulation, the lenders converted shares up to their limitations. Then when Radient released more shares into the float, the lenders would purchase shares.. This was done a number of times..We have saved our emails from the transfer agent with the outstanding share count and when they were released...4.5 billion shares accumulated in 35 days.


DCSPKA You said:

SRL Diagnostics India and AMDL Australia connection will be heating up now that AMDL Australia has chosen not to renew its corporate status. Lets see exactly what effect it will have on Radient/AMDL Diagnostics.

I am especially interested on the synergy between AMDL Australia & AMDL Diagnostics.

AMDL Diagnostics- come out, come out, where ever you are?

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111001885

Here's Jonny...Look who is checking out Jonny...

Jonny Deez
Orange County, California Area

https://www.linkedin.com/pub/jonny-deez/75/469/933?trk=pub-pbmap

Srinivas Yadav

it at AMDL Australia

Kurnool, Andhra Pradesh, India Medical Devices

https://www.linkedin.com/pub/srinivas-yadav/53/417/230?trk=pub-pbmap

Ikrar Khan

CSE at AMDL Australia
Noida Area, India Medical Devices

https://www.linkedin.com/pub/ikrar-khan/36/632/5a4?trk=pub-pbmap

Aussie with no mention of Radient..Go figure...Just a temp..lol

Darren Brown

Director at Cancer Screen Technologies Ltd

Melbourne Area, Australia
Management Consulting

Current

OnlineCapital Consulting, Cancer Screen Technologies Ltd

Previous

AMDL Australia, Hudson & Young, eWealthBuild Consulting


https://au.linkedin.com/in/dbrown197

***************************************************************



We have added these links to the SRL and Metropolis section of web sites. As you can see the two largest Diagnostics companies in India are selling Onko-Sure..SRL Limited and Metropolis Healthcare., Our sources told us that Metropolis is using the brand name Cancer 8 because SRL is using Onko-Sure.The 10 Million dollar deal with the India Government that was delayed in 2011 has apparently come to fruition. Radient had not filed their 2012,2013,2014 for a reason. To act like a private company without having to show the revenues from the India deal. The Indian deal consummated in 2013. On February 1, 2013, SRL sent out the first hint of the 10 million deal. Some will call this "India hype" or marijuana hype, whatever name was convenient at the time to falsely identity the true reasons for Large buying trading days over a two and a half years of accumulation.



http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=462

http://www.sec.gov/Archives/edgar/data/838879/000114420412039787/v318772_8k.htm

http://www.firstwordmedtech.com/node/942328

http://www.srlworld.com/wellness/content/160/niche-wellness-test.html

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111964442

Feb 4, 2013 0.00 0.00 0.00 0.00 126,054,600 0.00
Feb 1, 2013 0.00 0.00 0.00 0.00 389,462,900 0.00

http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=330


Radient is being restructured by a reverse merger. The majority of the stock is owned by institutional investors and Provista Diagnostics Angel investors. Someone mentioned that Radient was BROKE and should have gone bankrupt in June 2011 when indeed Radient was not in a bankrupt situation and to this day has never been. In Late September 2011, Radient was able to pay Alpha Capital the major 2011 lender 4.581,923 for the 4,559,842 million dollars to settle the 10.9 million owed to the :2011 lenders. The cash payment included 22,000 dollars of interest for one month after the settlement. The notes payable is reflected in the balance sheet from the last 10-K ending December 31, 2011.The remaining 6.0 million was converted into Radient stock by all of the 2011 lenders. The conversion took place after May 21, 2012 at .001 per share.
On May 21, 2012 Alpha and Whalehaven filed their SC 13 G's. In the settlement agreement the 2011 lenders were able to convert at .0001 per share.. The conversions started on May 25, 2012, according to the settlement before the 1/25 reverse split, Alpha was given 11,886,000 shares with protection, giving them 295 million shares. Whalehaven was given 9,114,000 shares which gives them after the reverse split, 127,850 million shares. In the agreement the 2011 collectively could not own more than 9.99 percent of the outstanding Radient stock..The 2011 at this time own 9.99 per cent of the RXPC stock and still holding. There is no way they would have converted at .001 and sold at .0001..That would give them less than 42,000 dollars...

The pps of the stock was at .02 before the conversions took place. The SC 13G's were filed on May 21, 2012..The conversions at .001 took place on May 25, 2012.

Jun 1, 2012 0.00 0.00 0.00 0.00 378,592,700 0.00
May 31, 2012 0.00 0.00 0.00 0.00 263,543,400 0.00
May 30, 2012 0.00 0.00 0.00 0.00 77,692,000 0.00
May 29, 2012 0.00 0.00 0.00 0.00 251,389,600 0.00
May 28, 2012 0.00 0.00 0.00 0.00 0 0.00
May 25, 2012 0.00 0.00 0.00 0.00 207,965,300 0.00
May 24, 2012 0.00 0.00 0.00 0.00 46,605,000 0.00
May 23, 2012 0.01 0.01 0.00 0.00 14,010,300 0.00
May 22, 2012 0.01 0.01 0.01 0.01 9,183,400 0.01
May 21, 2012 0.02 0.02 0.01 0.01 11,104,400 0.01

http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=528

Notes payable paid off in 2011.. Page 49 of the 10-K
4,581,923

http://www.sec.gov/Archives/edgar/data/838879/000114420412037312/v316641_10k.htm


Under the terms of the Final Settlement Agreement, we issued our 8% convertible promissory notes in the principal amount of $4,559,842.41 to Alpha Capital and $3,496,415.91 to Whalehaven (the “Notes”). We are obligated retire the Notes in monthly installments, commencing January 31, 2012, by the payment in cash or (at our sole option) by delivery shares of our common stock in an amount equal to 6.25% of the principal amount of each Note, plus accrued interest. In the event we elect to make installment payments in common stock, we will be obligated to make monthly delivery of shares of common stock that are not subject to any restrictions on resale under Rule 144 under the Securities Act (“Non-Restricted Shares”) valued at 80% of the three lowest volume weighted average closing prices of our common stock over the 20 trading days immediately prior to each installment payment date. It is our present intention to amortize the Notes with our common stock, although we may elect to pay one or more such installments in cash. ,

The Notes permit the Plaintiffs to convert the Notes into our common stock, although the Final Settlement Agreement and the Notes contain “blocker” provisions designed to prevent the Plaintiffs from becoming “beneficial owners” (as defined in Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act “) of more than 9.99% of our outstanding common stock, the Plaintiffs

We agreed to reserve an aggregate of 175.0 million shares of authorized and previously unissued Common Stock for potential issuance to the Plaintiffs for issuance upon their conversion of the Notes. We further agreed to keep a sufficient number of shares of Common Stock for purposes of enabling issuing all of the Settlement Shares pursuant to the Final Settlement Agreement and the Notes.


http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_8k.htm

This Final Settlement Agreement (the “Final Agreement”) is dated this 25th day of August 2011, to be effective as of August 19, 2011 (the “Effective Date”), is being entered into among Radient Pharmaceuticals Corporation (“RPC” or the “Company”), Whalehaven Capital Fund, Ltd. (“Whalehaven”) and Alpha Capital Anstalt (“Alpha Capital,” and together with Whalehaven, the “Plaintiffs” or the “Holder(s)”). The Company and the Holders are hereinafter sometimes collectively referred to as the “Parties.”

§ “Common Stock” means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.

“Converted Alpha Capital Notes” means notes aggregating $1,616,380.92 that were converted by Alpha Capital as part of the Initial Share Conversions into an aggregate of 11,886,000 Settlement Shares.

Converted Whalehaven Notes” means notes aggregating $1,239,415.76 that were converted by Whalehaven as part of the Initial Share Conversions into an aggregate of 9,114,000 Settlement Shares.

“Non-Restricted Shares” means shares of RPC Common Stock that are freely tradable, delivered without any restrictive legend and immediately resellable upon receipt by the Holder thereof pursuant to Rule 144(b)(1)(i) under the Securities Act of 1933, as amended, after November 2, 2011 without any additional holding period, volume limitations or manner of sale restrictions.

“Settlement Amount” shall mean the aggregate sum of $10,912,055 payable by the Company to the Plaintiffs under the Settlement Agreement and this Final Agreement, as to Alpha Capital in the amount of $6,176,223.13 and as to Whalehaven in the amount of $4,735,831.87.


http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_ex10-1.htm


CONVERTIBLE PROMISSORY NOTE

FOR VALUE RECEIVED, RADIENT PHARMACEUTICALS CORPORATION, a Delaware corporation (hereinafter called “Debtor”), hereby promises to pay to the order of ALPHA CAPITAL ANSTALT (the “Holder”), with an address at Pradafant 7, 9490 Furstentums, Vaduz, Lichtenstein, Fax: [phone], without demand, the sum of Four Million Five Hundred Fifty Nine Thousand Eight Hundred Forty Two Dollars Forty One Cents ($4,559,842.41) (“Principal Amount”), with interest accruing thereon, on April 15, 2013 (the “Maturity Date”), if not sooner paid or modified as permitted herein.

This Convertible Promissory Note (the “Note”) has been entered into pursuant to the terms of a Final Settlement Agreement by and among the Debtor, the Holder and another holder (the “Other Holder”) of a convertible promissory note (the “Other Note”), dated of even date herewith (the “Final Settlement Agreement”), for an aggregate Principal Amount of $8,056,258.32. Unless otherwise separately defined herein, each capitalized term used in this Note shall have the same meaning as set forth in the Final Settlement Agreement. The following terms shall apply to this Note:

http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_ex10-2.htm


Alpha Capital Anstalt

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -

6,496,317 shares of Common Stock
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

9.99%

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES x

The aggregate amount in Row 9 represents the maximum amount of shares that Alpha Capital Anstalt can beneficially control under a contractually stipulated 9.99% ownership restriction.

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

9.99%


http://www.sec.gov/Archives/edgar/data/838879/000121390012002926/sc13g052112alpha_radient.htm

Whalehaven Capital Fund Limited

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -

6,496,317 shares of Common Stock
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES x

The aggregate amount in Row 9 represents the maximum amount of shares that Whalehaven Capital Fund Limited can beneficially control under a contractually stipulated 9.99% ownership restriction.
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

9.99%

http://www.sec.gov/Archives/edgar/data/838879/000121390012002920/sc13g052112whale_radient.htm




We have concluded from the planned merger between Radient and Provista Diagnostics according to the LOI of 2010 and our completed analysis that Provista Diagnostics will either merge with Radient or reverse triangular merge Global Cancer Diagnostics with Radient.
The agreement between AMDL Diagnostics and Uni-Pharma and the agreement between Radient and Global Cancer Diagnostics were set up on a temporary basis and conveniently terminated after the last patent expired. Radient and Provista Diagnostics still have an exclusive 5 year agreement in force and Radient and Uni-Pharma are also in an exclusive and existing five year agreement. Those two agreements superseded the two previously terminated agreements. The Lung Cancer Test a/k/a LC Sentinel is still owned by Radient and Provista Diagnostics and included in their 5 year exclusive and collaborated agreement from November 2010 to research, develop, and commercialize cancer tests including the Lung Cancer Test. William Gartner sold his lung cancer and breast cancer to Provista Diagnostics in 2011.
The 4.5 billion RXPC shares outstanding are held by Institutional investors who had converted their debt for equity, and Angel investors who we believe are associated with Provista Diagnostics. After the announcement of revocation and insolvency, RXPC shares were accumulated and not sold. During the 2012 to July 3, 2014 period of trading,the creeping take over groups quietly took all the shares that Radient released slowly and in a timely manner to the public. If "ebabies" retailers etc that some are calling them were buying,they would have been the first to sell shares. As you can see from the lack of interest on this board before 2012 and after 2013...Enjoy our deductive logic approach to our premisses....

"Radient Is Being Restructured By A Planned Reverse Merger."

If:Radient wants and needs to be restructured by a merger and not by bankruptcy.

Then:Provista Diagnostics wants to go public

Therefore:Provista Diagnostics will merge according to the planned merger LOI of 2010 and the planned restructuring of Radient


*Uni-Pharma-Radient Dx Current Agreements and Past Agreement

http://finance.yahoo.com/news/Radient-Pharmaceuticals-iw-2457187542.html

http://contractservices.pharmaceutical-business-review.com/news/radient-expands-distribution-agreement-with-unipharma-221211

http://www.sec.gov/Archives/edgar/data/838879/000121390013003078/f8k061113ex10i_radientpharm.htm


*Radient Dx and Provista-Global Cancer Dx Current Agreements

http://www.marketwired.com/press-release/Radient-Pharmaceuticals-Announces-Exclusive-5-Year-Laboratory-Services-Agreement-With-NYSE-Amex-RPC-1345331.htm

http://www.sec.gov/Archives/edgar/data/838879/000114420412039787/v318772_ex10-1.htm

*Radient Dx and Provista DX /Global Cancer DX Lung Cancer Test

http://www.pharmaceuticalonline.com/doc/radient-pharmaceuticals-and-provista-life-0001

http://www.bizjournals.com/phoenix/print-edition/2011/12/30/provista-to-go-public-with-breast.html

http://www.biocentury.com/products/lc_sentinel


*Over 38 Million Dollars Lender Debt Converted to Stock

http://www.prnewswire.com/news-releases/radient-pharmaceuticals-corporation-completes-restructurings-with-institutional-investors-to-limit-conversions-and-stock-sales-and-provide-for-potential-additional-capital-134659763.html

http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_8k.htm

http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_ex10-1.htm

http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_ex10-2.htm

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112765409

http://seekingalpha.com/instablog/424698-m-e-garza/177461-regarding-latest-8k-filing-by-radient-pharmaceuticals-rpc

*All Accounts Payable Paid in Full By GCDx and Uni-Pharma Royalties/ License Agreements,Onko-Sure Sales in India,Taiwan,Korea,etc.and Attorney Debt to Equity Agreement

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112733314

*SRL Limited and Metropolis Healthcare Currently Selling Onko-Sure/Cancer 8 Throughout India

http://www.west-info.eu/it/analisi-del-sangue-13-tipi-tumore-cancro/2012-02-onkosure-fibrin-fdp-in-cancer-mm-2/

http://www.srlworld.com/wellness/content/160/niche-wellness-test.html

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111964442

http://www.metropolisindia.com/patients/cancer-eight


*Institutional Shareholders

http://www.prnewswire.com/news-releases/radient-pharmaceuticals-corporation-completes-restructurings-with-institutional-investors-to-limit-conversions-and-stock-sales-and-provide-for-potential-additional-capital-134659763.html

http://www.sec.gov/Archives/edgar/data/838879/000121390012000035/0001213900-12-000035-index.htm

http://www.sec.gov/Archives/edgar/data/838879/000121390012002920/sc13g052112whale_radient.htm

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=7538329

http://msnmoney.brand.edgar-online.com/DisplayFilingInfo.aspx?TabIndex=2&FilingID=7717117&type=html&companyid=4985&ppu=%2fDefault.aspx%3fticker%3drpc

http://www.sec.gov/Archives/edgar/data/838879/000136456011000007/stgeo_sc13g.htm

http://www.sec.gov/Archives/edgar/data/838879/000101968711002819/bristol_13ga-082411.htm

http://www.sec.gov/Archives/edgar/data/838879/000121390011003768/sc13g0711a1whale_radient.htm

http://www.sec.gov/Archives/edgar/data/838879/000121390011003763/sc13g0711a1alpha_radient.htm

http://www.sec.gov/Archives/edgar/data/838879/000090266411001142/p11-1347sc13g.htm

http://www.sec.gov/Archives/edgar/data/838879/000101968712000550/bristolradient_13ga2.htm

http://www.sec.gov/Archives/edgar/data/838879/000119312512059770/d301526dsc13ga.htm

http://www.sec.gov/Archives/edgar/data/838879/000090266412000289/p12-0319sc13ga.htm

Conclusion:

http://provistadx.com/

http://globalcancerdx.com/

http://azbio.tv/video/76134461f30e472d8f08be36f73bc095

http://seekingalpha.com/instablog/8702411-underdawg/2186492-the-many-veils-of-radient-pharmaceuticals-onko-sure-drminus-70

The link below will guide you to the complete analysis to our premisses.

"Radient Restructured By A Planned Reverse Merger"

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113309714

Radient Is Being Restructured by A Reverse Merger


Part 1 April 20, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112893006


Part 2 April 21, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112930694


Part 3 April 22, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112973321

Part 4 April 23, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113014648

Part 5 April 24, 2015 Rebuttals

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113056841

Part 6 April 25, 2015 Rebuttals

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113091753

Conclusion: April 26, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113104999

Uni-Pharma Part 1 April 27, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113119285

Uni-Pharma Part 2 April 28, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113155567

Uni-Pharma Part 3 - Global Cancer Diagnostics Part 1
April 29, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113192928

GCDX and Uni-Pharma April 30, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113228108

Uni-Pharma Conlusion May 1, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113264286




May 2, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113295899

May 3, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113309714

May 4, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113319076

May 5, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113362336

May 6, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113388535

May 7, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113443502

mAY 8,2015 AND MAY 9,2015


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113503925

May 10,2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113512169


All Roads Lead To Scottsdale, Arizona and Taipei,Taiwan Uni-Pharma Partnering with Global Cancer Diagnostics to Manufacture and Distribute Onko-Sure Overseas.